Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ROCKVILLE, Md., Oct. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that Thomas H. Bliss, Jr., EntreMed's Senior Vice President, Corporate and Business Development, will present a Company overview at the 16th Annual BioPartnering Europe Conference, which is being held October 12-14, 2008 in London, United Kingdom. Mr. Bliss' presentation is scheduled for Monday, October 13, 2008 at 12:15 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Bliss will provide an overview of the Company's clinical-stage programs, with particular emphasis on ENMD-2076 and 2ME2 for rheumatoid arthritis. ENMD-2076, an orally-active, Aurora/angiogenesis inhibitor for the treatment of cancer, is in a multi-center Phase 1b dose-escalation study in patients with solid tumors. Panzem(R) (2ME2), an orally-active small molecule angiogenesis inhibitor with disease modifying properties for the treatment of rheumatoid arthritis (RA), has completed a Phase 1 clinical trial in healthy volunteers. EntreMed is actively marketing ENMD-2076 and 2ME2 for RA to prospective pharmaceutical and biotech company partners as a means to accelerate the development and commercialization of these novel drug candidates.

Mr. Bliss's presentation will not be web cast; however, a copy of his presentation will be available through the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical compa
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Look inside the new Preferred Solutions® catalog ... from fluid handling to instruments to supplies. Many items ... order. , Preferred Solutions features a full selection ... model for precise flow control and dispensing to I/P® ...
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... 2013 was a banner year of ... They saw continued independent research led by the team ... a $1 million grant from the Susanne Marcus Collins ... a peer reviewed journal, Amy Grant highlighted Brainwave Optimization® ...
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... Jan. 6, 2011 Cellular Dynamics International, Inc. (CDI), ... (iPS) cell lines and tissue cells for drug discovery ... to present at the 29th Annual JPMorgan Healthcare Conference ... Westin St. Francis Hotel in San Francisco. Robert Palay, ...
...  MacroGenics, Inc., a privately held biotechnology company that ... infectious diseases, today announced that it had administered ... a Phase I clinical trial of MGAH22.  MGAH22 ... which has been shown, in pre-clinical studies, to ...
... This release is available in Spanish . ... leading in Spain the European project within the VII Framework ... buildings which host large numbers of people, such as sports ... by the management and optimisation of energy in its three ...
Cached Biology Technology:MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors 2MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors 3MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors 4Tecnalia leads the integration of energy efficiency in sports facilities 2
(Date:4/24/2014)... very pleased to announce that it has assumed ownership ... the University of Wisconsin. , The Journal ... peer-reviewed journal that publishes papers on all aspects of ... the molecular to the ecological -- as well as ... to individuals and institutions, and it provides a reasonably ...
(Date:4/24/2014)... study of animal intelligence to-date finds that animals with bigger ... week in the journal Proceedings of the National Academy ... history of research aimed at understanding the animal mind. Specifically, ... and use tools, read social cues, or even understand basic ... of animal intelligence have focused on only one or a ...
(Date:4/24/2014)... returning home from Iraq and Afghanistan, post-traumatic stress disorder ... institutions and the culture at-large. Estimates indicate that as ... and Afghanistan suffer from PTSD. New research from the ... light on how PTSD is linked to other diseases ... PTSD has implications beyond the impact of the psychiatric ...
Breaking Biology News(10 mins):ESA to publish the Journal of Insect Science 2Animals with bigger brains, broader diets have better self control 2Animals with bigger brains, broader diets have better self control 3New study links inflammation in those with PTSD to changes in microRNA 2New study links inflammation in those with PTSD to changes in microRNA 3
... Researchers at Washington University in St. Louis and Arizona State University ... energy by making an even rarer form of chlorophyll, chlorophyll d. ... invisible to the naked eye. , ... competes with virtually no other plant or bacterium in the world ...
... Disclosure Project (CDP) a collaboration of 385 institutional investors, ... its 2008 information request to the worlds largest corporations. ... gas emissions and report on their strategy for dealing ... The resulting information will be held on the ...
... of the most important metabolic processes in our bodies, ... intermediates have been produced in multigram quantitieswith one exception, ... University of Leipzig have finally done it. As they ... combination of one biotechnological and one chemical step, starts ...
Cached Biology News:Bacterium sequenced makes rare form of chlorophyll 2Bacterium sequenced makes rare form of chlorophyll 3World's largest investor coalition seeks further disclosure on climate change and shareholder value 2World's largest investor coalition seeks further disclosure on climate change and shareholder value 3Kilogram quantities at last! 2
... single use spatulas have been designed to ... are for those interested in eliminating the ... Each spatula is individually packaged, RNase/DNase free, ... is a new product number, created to ...
... Alkaline Phosphatase Detection Kit (Catalog number SCR004) ... the phenotypic assessment of ES cell differentiation ... Available separately from CHEMICON are the monoclonal ... (Catalog Number MAB4354), which permit the detection ...
... complete, flexible system designed specifically for ... is frequently required in biological research. ... miniature Clark-style polarographic electrode. Measuring only ... (3.2 mm), it is ideal for ...
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
Biology Products: